OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Role of PD Biomarkers in Biosimilar Development – To Get the Right Answer One Must First Ask the Right Question
Gillian R. Woollett, Joseph P. Park, Jihyun Han, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 1, pp. 50-54
Open Access | Times Cited: 6
Gillian R. Woollett, Joseph P. Park, Jihyun Han, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 1, pp. 50-54
Open Access | Times Cited: 6
Showing 6 citing articles:
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer’s Perspective
Hillel P. Cohen, Matthew Turner, Dorothy McCabe, et al.
BioDrugs (2023) Vol. 37, Iss. 5, pp. 583-593
Open Access | Times Cited: 18
Hillel P. Cohen, Matthew Turner, Dorothy McCabe, et al.
BioDrugs (2023) Vol. 37, Iss. 5, pp. 583-593
Open Access | Times Cited: 18
Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
Tomás Gabriel Bas, Vannessa Duarte
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 925-925
Open Access | Times Cited: 2
Tomás Gabriel Bas, Vannessa Duarte
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 925-925
Open Access | Times Cited: 2
Advancing Innovations in Biosimilars
Yow‐Ming Wang, David G. Strauss
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 1, pp. 11-15
Open Access | Times Cited: 9
Yow‐Ming Wang, David G. Strauss
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 1, pp. 11-15
Open Access | Times Cited: 9
Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments
Ryosuke Kuribayashi, Aya Hariu, Ayuki Nakano, et al.
Pharmaceutical Medicine (2024) Vol. 38, Iss. 3, pp. 225-239
Closed Access
Ryosuke Kuribayashi, Aya Hariu, Ayuki Nakano, et al.
Pharmaceutical Medicine (2024) Vol. 38, Iss. 3, pp. 225-239
Closed Access
Advice to the US FDA to Allow US Pharmacopeia to Create Biological Product Specifications (BPS) to Remove Side-by-Side Analytical Comparisons of Biosimilars with Reference Products
Sarfaraz K. Niazi
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1013-1013
Open Access
Sarfaraz K. Niazi
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1013-1013
Open Access
Trend Analysis of Regulatory Approvals for Generics and Biosimilars in Japan: 15 Years of PMDA During Fiscal Years 2009–2023
Ryosuke Kuribayashi, Kanoko Goto, Takumi Ogawa
The AAPS Journal (2024) Vol. 26, Iss. 6
Closed Access
Ryosuke Kuribayashi, Kanoko Goto, Takumi Ogawa
The AAPS Journal (2024) Vol. 26, Iss. 6
Closed Access
